Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

49.68 -0.21 (-0.42%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 198,085
Open 49.54
Bid (Size) 48.61 (1)
Ask (Size) 50.90 (1)
Prev. Close 49.89
Today's Range 48.61 - 50.17
52wk Range 37.08 - 130.33
Shares Outstanding 78,684,039
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
  Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday. 
Via Benzinga
Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates
 
Via Benzinga

Performance

YTD
-58.13%
-58.13%
1 Month
-4.75%
-4.75%
3 Month
-15.88%
-15.88%
6 Month
+7.67%
+7.67%
1 Year
-56.09%
-56.09%

More News

Read More
Recap: Intellia Therapeutics Q3 Earnings
Via Benzinga
Earnings Preview For Intellia Therapeutics
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Via Investor's Business Daily
7 Analysts Have This to Say About Intellia Therapeutics
Via Benzinga
Intellia Therapeutics Shares Are Gaining After Positive Data From Second CRISPR Candidate
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Via Benzinga
3 Cathie Wood Stocks to Buy and Hold for 10 Years
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Via Benzinga
The Top 5 Stocks Cathie Wood Is Buying This Week
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
Via Benzinga
5 Top Stocks Cathie Wood Is Buying Right Now
Via InvestorPlace
SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To Know
Via Benzinga
What 4 Analyst Ratings Have To Say About Intellia Therapeutics
Via Benzinga
This Analyst Cuts PT On Adobe, Plus Barclays Predicts $240 For FedEx
Via Benzinga
Why Is Applied Optoelectronics (AAOI) Stock Up 35% Today?
Via InvestorPlace
Why Is Esports Entertainment (GMBL) Stock Down 45% Today?
Via InvestorPlace
What Is Going on With Intellia Therapeutics (NTLA) Stock Today?
Via InvestorPlace
Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies
Via Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Via Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
Via Investor's Business Daily
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Intellia Gets FDA Orphan Drug Status For Hereditary Angioedema Candidate
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.